INmune Bio Inc (NAS:INMB)

Q2 2026 INmune Bio Inc Earnings Call Transcript

Aug 6, 2026 / 08:30 PM GMT

Release Date Price: $1.91 (+0.26%)

Transcript

Key Points

Positve

INmune Bio Inc (INMB) secured formal MHRA alignment and approval of the pediatric investigation plan, materially reducing regulatory risk ahead of the planned UK marketing authorization application (MAA) submission by end of Q3 or early Q4 2026.
The company completed a key commercial manufacturing milestone at the Cell and Gene Therapy Catapult facility, processing the first commercial-ready umbilical cord and transferring the MSC isolation stage into the intended commercial facility, strengthening the long-term supply chain.
INmune Bio Inc (INMB) received FDA Fast-Track designation for XPro in early Alzheimer's disease, and the Phase II mindful study showed statistically significant treatment effects on white matter myelin MRI biomarkers (P=0.0028, Cohen's effect size 0.46).
The company's net loss for Q2 2026 was significantly reduced to approximately $1.3 million, compared to $24.5 million in Q2 2025, with the prior period including a $16.5 million impairment charge.
INmune Bio Inc (INMB) received approximately $4.2 million in Australian R&D tax rebates subsequent to quarter end, providing non-dilutive capital, and believes existing cash resources are sufficient to fund operations into Q2 2027.
The Cordstrom platform patent application entered the U.S. national phase following a favorable international written opinion, potentially providing broad protection into at least 2045.

Negative

INmune Bio Inc (INMB) faces significant regulatory and operational hurdles in submitting the MAA to the MHRA by end of Q3 or early Q4 2026, with the EMA submission planned for early 2027 and the U.S. BLA in Q1 2027, leaving a tight timeline for multiple filings.
The company's cash position of approximately $18.4 million as of June 30, 2026, is relatively low, and management acknowledges the need to raise additional capital, with a burn rate of $1 million to $1.5 million per month.
INmune Bio Inc (INMB) is heavily dependent on the success of Ebstracell for near-term value, and any delays or negative feedback from regulatory agencies could significantly impact the company's prospects.
The Phase III confirmatory trial for Ebstracell is expected to enroll 40-45 patients with data available around mid-2028, meaning the company will not have confirmatory data for several years, which could affect conditional approval sustainability.
The company's focus on Ebstracell means the XPro program for Alzheimer's disease is being deprioritized, and management is evaluating strategic partnerships, which could dilute value or result in less favorable terms for shareholders.
INmune Bio Inc (INMB) faces pricing and reimbursement uncertainties in the UK, with negotiations expected to start only after filing the MAA, and the company's projected pricing of £400,000-£500,000 per year per child may face pushback from payers.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

INMB.OQ - INmune Bio Inc
Q2 2026 INmune Bio Inc Earnings Call
Aug 06, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to Immune BIOS Second Quarter 2026 Earnings Call.

At this time, all participants are in a listen-only mode. Following the presentation, there will be a question-and-answer session, at which time you may press *1 to ask a question.

As a reminder, this conference call is being recorded. A transcript will be available approximately 24 hours after the.

Before we begin, please note that except for statements of historical fact, statements made by management and responses to questions may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1,995.

These statements involve risks and uncertainties that could cause actual

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.